Behavioral Effects and Pharmacokinetics of (±)-3,4-Methylenedioxymethamphetamine (MDMA, Ecstasy) after Intragastric Administration to Baboons

Goodwin, Amy K.; Mueller, Melanie; Shell, Courtney D.; Ricaurte, George A.; Ator, Nancy A.

doi:10.1124/jpet.113.203729

Cited by 5 publications

(6 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Behavioural observations revealed increased frequency of non-specified bruxism as the dose of MDMA was increased. 36 A theory suggests that MDMA induces the release of serotonin, which may result in reduced dopaminergic activity at the prefrontal cortex. Deficiency of dopamine contributes to the development of bruxism.…”

Section: Methylenedioxymethamphetaminementioning

confidence: 99%

Medications and addictive substances potentially inducing or attenuating sleep bruxism and/or awake bruxism

Baat

Verhoeff

Ahlberg

et al. 2020

J of Oral Rehabilitation

View full text Add to dashboard Cite

Bruxism is a repetitive jaw‐muscle activity characterised by clenching or grinding of the teeth and/or by bracing or thrusting of the mandible. It can occur during sleep, indicated as sleep bruxism, or during wakefulness, indicated as awake bruxism. Exogenous risk indicators of sleep bruxism and/or awake bruxism are, among others, medications and addictive substances, whereas also several medications seem to have the potential to attenuate sleep bruxism and/or awake bruxism. The objective of this study was to present a narrative literature on medications and addictive substances potentially inducing or aggravating sleep bruxism and/or awake bruxism and on medications potentially attenuating sleep bruxism and/or awake bruxism. Literature reviews reporting evidence or indications for sleep bruxism and/or awake bruxism as an adverse effect of several (classes of) medications as well as some addictive substances and literature reviews on medications potentially attenuating sleep bruxism and/or awake bruxism were used as starting point and guidelines to describe the topics mentioned. Additionally, two literature searches were established on PubMed. Three types of bruxism were distinguished: sleep bruxism, awake bruxism and non‐specified bruxism. Generally, there are insufficient evidence‐based data to draw definite conclusions concerning medications and addictive substances inducing or aggravating sleep bruxism and/or awake bruxism as well as concerning medications attenuating sleep bruxism and/or awake bruxism. There are insufficient evidence‐based data to draw definite conclusions concerning medications and addictive substances inducing or aggravating sleep bruxism and/or awake bruxism as well as concerning medications attenuating sleep bruxism and/or awake bruxism.

show abstract

Section: Methylenedioxymethamphetaminementioning

confidence: 99%

Medications and addictive substances potentially inducing or attenuating sleep bruxism and/or awake bruxism

Baat

Verhoeff

Ahlberg

et al. 2020

J of Oral Rehabilitation

View full text Add to dashboard Cite

show abstract

“…Three studies assessed stereotypies in non-rodent animals, specifically monkeys, after chronic MDMA administration. All of them found no effect on stereotypy levels [ 120 - 122 ]. All studies tested only males, however, with singular and chronic doses of 0.32-7.8 mg/kg by intramuscular, oral or intragastric administration [ 120 - 122 ].…”

Section: Resultsmentioning

confidence: 99%

“…All of them found no effect on stereotypy levels [ 120 - 122 ]. All studies tested only males, however, with singular and chronic doses of 0.32-7.8 mg/kg by intramuscular, oral or intragastric administration [ 120 - 122 ].…”

Section: Resultsmentioning

confidence: 99%

A Systematic Review of the MDMA Model to Address Social Impairment in Autism

Chaliha

Mamo

Albrecht

et al. 2021

View full text Add to dashboard Cite

Background: Autism Spectrum Disorder (ASD) is a neurodevelopmental disorder characterised by repetitive behaviours, cognitive rigidity/inflexibility, and social-affective impairment. Unfortunately, no gold-standard treatments exist to alleviate the core socio-behavioural impairments of ASD. Meanwhile, the prosocial empathogen/entactogen 3,4- methylene-dioxy-methamphetamine (MDMA) is known to enhance sociability and empathy in both humans and animal models of psychological disorders. Objective: We review the evidence obtained from behavioural tests across the current literature, showing how MDMA can induce prosocial effects in animals and humans, where controlled experiments were able to be performed. Methods: Six electronic databases were consulted. The search strategy was tailored to each database. Only Englishlanguage papers were reviewed. Behaviours not screened in this review may have affected the core ASD behaviours studied. Molecular analogues of MDMA have not been investigated. Results: We find that the social impairments may potentially be alleviated by postnatal administration of MDMA producing prosocial behaviours in mostly the animal model. Conclusion: MDMA and/or MDMA-like molecules appear to be an effective pharmacological treatment for the social impairments of autism, at least in animal models. Notably, clinical trials based on MDMA use are now in progress. Nevertheless, larger and more extended clinical studies are warranted to prove the assumption that MDMA and MDMA-like molecules have a role in the management of the social impairments of autism.

show abstract

“…Absorption is the process by which a drug enters the organism and the circulatory system. In contrast, MDA is not the major metabolite of MDMA in NHPs and humans; the amount of MDA that results from MDMA metabolism in NHPs is approximately 10-fold less than in rodents [22][23][24]. Metabolism is the chemical modification of the drug to active and/or inactive entities.…”

Section: Pharmacokineticsmentioning

confidence: 99%